Approval · Notice of Compliance 30540 · 2023
BEYFORTUS: Notice of Compliance 30540
Issued April 19, 2023
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 30540
- Date
- April 19, 2023
- Company
- Astrazeneca Canada IncMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
Products in this notice
Medicinal ingredients
- NIRSEVIMAB 50 MG per 0.5ML
- NIRSEVIMAB 100 MG per ML